Effect of incentive spirometry in prevention of acute chest syndrome during painful crisis in adult sickle cell patients

Effect of incentive spirometry in prevention of acute chest syndrome during painful crisis in adult sickle cell patients - Spirometry and Acute Chest Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34975

Enrollment

Registered

2010-03-04

Start date

2010-05-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sickle cell anemia sickling of the lungs

Interventions

Patients in the study group will be educated in the use of the spirometer (Respiflo*FS, Kendall) and the study protocol by the investigator. During admission patients have to inhale10 times through

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: High performance liquid chromatography confirmed diagnosis of HbSS, HbSC, HbSB0- or HbSB+-thalassemia genotypes. Written informed consent by the patient. Thoracic or back pain above the diaphragm. Hospital admission due to vaso-occlusive painful crisis.

Exclusion criteria

Exclusion criteria: Blood transfusion in the preceding three months Diagnosis of Acute Chest Syndrome at presentation

Design outcomes

Primary

Measure	Time frame
1. To evaluate the efficacy of incentive spirometry in primary prevention of ACS in adult sickle cell patients during painful crisis.	—

Secondary

Measure	Time frame
1. To relate the efficacy of incentive spirometry to plasma levels of phospholipase A2 and serum levels of procalcitonine. 2. To evaluate whether plasma sPLA2 levels may be helpful to stratify patients in high and low risk groups and to evaluate the value of incentive spirometry in these groups to prevent ACS. 3. To evaluate whether serum procalcitonine may stratify patients with an ACS related to an infectious and non-infectious pathogenesis and to evaluate the value of incentive spirometry to prevent ACS. 4. To identify the micro bacterial organisms responsible for the development of an acute chest syndrome and to relate this with the procalcitonin plasma levels.	—

Measure

Time frame

1. To relate the efficacy of incentive spirometry to plasma levels of phospholipase A2 and serum levels of procalcitonine. 2. To evaluate whether plasma sPLA2 levels may be helpful to stratify patients in high and low risk groups and to evaluate the value of incentive spirometry in these groups to prevent ACS. 3. To evaluate whether serum procalcitonine may stratify patients with an ACS related to an infectious and non-infectious pathogenesis and to evaluate the value of incentive spirometry to prevent ACS. 4. To identify the micro bacterial organisms responsible for the development of an acute chest syndrome and to relate this with the procalcitonin plasma levels.

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)